Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 6
Journal homepage
3
Views
0
CrossRef citations to date
0
Altmetric
Biotechnology & Immunology

Overview: Exploitation of the Contrasting Immunomodulatory Characteristics of Interleukin-2 - A Review and Comment on Recent Patent Literature

David B Gough Brigham and Women's Hospital, Boston, USA
Pages 871-881 | Published online: 02 Mar 2011

References to Primary Literature

  • Stinnett ID, Alexander JW, Morris MJ, Dreffer RL, Craycraft TK, Anderson PE, Ogle CK, MacMillan BG Improved survival in severely burned animals using Cornybacterium parvum vaccine post injury. Surgery 1981 89 237–242.
  • Robb RJ Interleukin-2: The molecule and its function. Immunol. Today 1984 5 203–209.
  • Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichart CM Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Eng. J Med. 1985 313 1485–1490.
  • Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA In vitro growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologous tumour by human lymphocytes cultured in T cell growth factor. Cancer Res. 1981 41 4420–4425.
  • Yron I, Wood TA Jnr., Spiess PJ, Rosenberg SA In vivo growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumours. J. Immunol. 1980 125 238–245.
  • Michie HR, Eberlein TJ, Spriggs DR, Manogue KR, Cerami A, Wilmore DW Interleukin-2 initiates metabolic responses associated with critical illness in humans. Ann. Surg. 1988 208 493–503.
  • Michie HR, Spriggs DR, Dinarello CA, Cerami A, Wolff SM, Kufe DW, Wilmore DW Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988 104 280–286.
  • Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res. 1988 48 5007–5010.
  • Gough DB Educate the phagocyte!. Br. J. Surg. 1991 78 1–2.
  • West WH, Tauer KW, Yaneli JR, Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N. Eng. J. Med. 1987 316 898–905.
  • Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Special report. Use of tumour infilltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Eng. J. Med. 1988 319 1676–1680.
  • Avella J, Binder HJ, Madsen JE, Askenase PW Effect of histamine H2-receptor antagonists on delayed hypersensitivity. Lancet 1978 1 624.
  • Mitchell MM, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC Effectiveness and tolerability of low dose cyclophosphamide and low dose intravenous interleukin-2 in disseminated melanoma. J. Clin. Oncol. 1988 6 409.
  • Wadler S, Wiernik PH Clinical update on the role of fluorouracil and recombinant interferon α2a in the treatment of colorectal carcinoma. Semin. Oncol. 1990 17 Suppl. 16–21.
  • Wood JJ, O'Mahony JB, Rodrick ML, Eaton R, Demling RH, Mannick JA Abnormalities of antibody production after thermal injury. An association with reduced interleukin-2 production. Arch. Surg. 1986 121 108–115.
  • Beutler B, Cerami A Cachectin: More than a tumour necrosis factor. N. Eng. J. Med. 1987 316 1481–1486.
  • Glauser MP, Zanetti G, Baumgartner JD, Cohen J Septic shock: Pathogenesis. Lancet 1991 338 732–736.
  • Fletcher JR Ibuprofen in patients with severe sepsis. Crit. Care Med. 1991 19 1331–1332.
  • Pirisino R, Di Simplicio P, Ignesti G, Bianchi G, Barbera P Sulphydrl groups and peroxi dase-like activity of albumin as scavenger of organic peroxides. Pharmacol. Res. Commun. 1988 20 545–552.
  • McCartney AC, Browne MK Clinical studies on the administration of Taurolin in severe sepsis: A preliminary study. Bacterial endotoxins; Pathophysiological effects, clinical significance and pharmocological control Alan R Liss, Inc. New York 1988 130.
  • Dunn DL, Ewald DC, Chandan N, Cerra FB Immunotherapy of gram-negative sepsis. A single murine monoclonal antibody provides cross-genera protection. Arch. Surg. 1986 121 58–62.
  • Ziegler EJ, Fischer CJ Jnr., Sprung, Treatment of gram-negative bacteraemia and septic shock with HA-1A human monoclonal antibody against endotoxin - a randomised, doubleblind, placebo-controlled trial. N. Eng. J. Med. 1991 324 429–436.
  • Reidy JJ, Ramsay G Clinical trials of selective decontamination of the digestive tract: A review. Crit. Care Med. 1990 18 1449–1456.
  • Moore FA, Moore EE, McAnena O, Poggetti R, Abernathy CM, McCroskey BL, Parsons PE Gut bacterial translocation via the portal vein: A clinical perspective with major torso trauma. J. Trauma. 1991 31 629–638.
  • Galanos C, Freudenberg MA, Matsuura M, Coumbos A Hypersensitivity to endotoxin and mechanisms of host-response. Bacterial endotoxins: Pathophysiological Effects, Clinical Significance, and Pharmacological Control Alan R Liss Inc 1988, 295–308.
  • Harris RL, Stone PCW, Stuart J Endotoxaemia as a cause of fever in immunosuppressed patients. J. Clin. Path. 1984 37 467–470.
  • Jacob Al, Goldberg PK, Bloom N, Degenshein GA, Kozinn PJ Endotoxin and bacteria in portal blood. Gastroenterol. 1977 72 1268–1270.
  • Michie HR, Guillou P, Wilmore DW Tumor necrosis factor and bacterial sepsis. Br. J. Surg. 1989 76 670–671.
  • Moss NM, Gough DB, Jordan AL, Grbic JT, Wood JJ, Rodrick ML, Mannick JA Temporal correlation of impaired immune response after thermal injury with susceptibility to infection in a murine model. Surgery 1988 104 882–887.
  • Gough DB, Moss NM, Jordan A, Grbic JT, Rodrick ML, Mannick JA Recombinant IL-2 (rIL-2) improves immune response and host resistance to septic challenge in thermally injured mice. Surgery 1988 104 293–300.
  • Horgan PG, Mannick JA, Dubravec DB, Rodrick ML Effect of low dose recombinant interleukin-2 plus indomethacin on mortality after sepsis in a murine burn model. Br. J. Surg. 1990 77 401–404.
  • Gough DB, Winstanley FP, Fearon KCH, Carter DC Regulation of TNF production in healthy humans and in patients with cancer. Arch. Surg. In press.
  • Hancock WW, Muller WA, Cotran RS Interleukin 2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macroph -ages, blood monocytes, and monocyte cell lines. J. Immunol. 1987 138 185–191.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.